ASP Isotopes (NasdaqCM:ASPI) Conference February 25, 2026 09:05 AM ET Company ParticipantsAnna Berry - HostPaul Mann - Chairman and CEOAnna Berryeveryone to the 90th Emerging Growth Conference and day one of our two-day virtual investor conference. I'm Anna Berry. Just a few notes. Today, we're running until about 4:50 P.M. Eastern. When we switch to the next company, you'll see a black screen for a moment. Don't go anywhere. That's just us moving to the next presentation. If you do experience downtime for ...

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5] - The company has secured a contract for silicon-28 and aims to fulfill customer orders by 2026 [4] Company Strategy and Development Direction - The company aims to diversify its operations beyond South Africa and expand its radiopharmaceutical footprint globally [70] - Quantum Leap Energy (QLE) plans to secure the nuclear supply chain and has raised $64.3 million via convertible notes to support its initiatives [13][14] - The acquisition of Skyline Builders is part of a strategy to secure critical material supply chains essential for the U.S. and ASP Isotopes [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the enrichment processes [38] - The focus for the next six months includes completing the Renergen acquisition and achieving operational de-risking by the end of Q1 2026 [39][40] - The company is committed to providing further guidance on revenue projections as clarity improves internally [52][53] Other Important Information - The company is planning to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][50][52] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns of capital commitments and revenue opportunities will be provided in future updates [54][55] Question: Can you discuss the opportunity for LEU Plus? - LEU Plus is a new focus based on customer inquiries, aimed at increasing power density and extending the life of existing nuclear power plants [56][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift away from construction [64][66]

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31][32] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [31][32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32][33] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4][5] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5][6] - The company is expanding its radiopharmaceutical operations globally, with the first purchase in the U.S. announced for East Coast Nuclear in Florida [10] Company Strategy and Development Direction - The company aims to secure supply chains of critical materials essential to the U.S. and ASP Isotopes, with recent acquisitions supporting this strategy [21][22] - Quantum Leap Energy (QLE) plans to produce lithium-7 and lithium-6 isotopes to meet the growing demand in the nuclear industry [15][16] - The company is focused on operational de-risking and plans to complete the Renergen acquisition and IPO of QLE in the near future [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the silicon-28 enrichment process [38] - The company anticipates significant revenue opportunities in 2026 and 2027, particularly around ytterbium-176 and silicon-28 [49][50] Other Important Information - The company has raised $64.3 million via convertible notes, bringing pro forma cash on hand to $81.6 million [13] - The company is planning to construct new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29][30] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December 2025, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Can you discuss the revenue opportunity for Ytterbium-176 and Silicon-28? - The company is maintaining previous revenue guidance of $50-$70 million for 2026 and 2027 [49][50] Question: What is the capital commitment for building new facilities in 2026? - Detailed capital commitment information will be provided in future updates [54][55] Question: Can you elaborate on the LEU Plus opportunity? - LEU Plus is a subcategory of HALEU, driven by customer inquiries, aimed at increasing power density and extending the life of nuclear power plants [56][60] Question: Should the $3 million revenue from Skyline Builders be modeled going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift to securing the nuclear supply chain [64][66]

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The acquisition of Renergen is nearing completion, with all but one regulatory approval received, expected imminently [5] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Market Data and Key Metrics Changes - The company has secured contracts for silicon-28 and is looking to satisfy all current customer orders in 2026 [4] - The acquisition of Skyline Builders aims to secure supply chains of critical materials essential to the U.S. and ASP Isotopes [21] Company Strategy and Development Direction - The company is focused on expanding its isotope enrichment capabilities and has plans for multiple new production facilities [8][28] - Quantum Leap Energy aims to stabilize the nuclear supply chain and is developing technologies for lithium-7 and HALEU production [12][18] - The company is also investing in radiopharmaceutical operations, with plans to expand into the U.S. market [11][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational progress and customer relationships, emphasizing the importance of completing phase 1C for de-risking projects [39] - The company anticipates significant revenue opportunities in 2026 and 2027, particularly around ytterbium-176 and silicon-28 [49] - Management acknowledged the complexities of the isotope industry and the need for transparency with investors regarding future projections [50][52] Other Important Information - The company is preparing for the IPO of Quantum Leap Energy, with S-1 documentation filed with the SEC [13][27] - The company plans to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K. during 2026 [28] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of starting up the plant and modifications agreed upon with customers, but operations are currently going well [37] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Expected by the end of the first quarter, focusing on completing phase 1C [39] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue from carbon is expected to ship by the end of December, with silicon isotopes expected to generate revenue in 2026 [41] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers are satisfied with the results of the samples, indicating that the technology works [43][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][53] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns will be provided in future updates, but specifics are not available at this time [54][55] Question: Can you talk about the opportunity for LEU Plus? - LEU Plus is a subcategory of HALEU, driven by customer inquiries, and is expected to enhance power density and extend refueling cycles for existing plants [58][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - This revenue is not expected to continue, as the focus will shift away from construction activities [63]

Business Updates - ASP Isotopes secured its largest Silicon-28 contract to date with a new U S based customer for delivery during 2026[10] - The company expects to receive large quantities of feedstock suitable for Carbon-14 production during January 2026, with the first shipment of enriched Carbon-14 during 1H 2026[22] - Quantum Leap Energy (QLE) acquired a Nuclear Waste Processing Company and signed a Memorandum of Understanding (MOU) with Fermi America for uranium isotope enrichment[30] - QLE acquired "One30Seven" accelerated beta-decay technology and is developing cesium-137 to barium-137 Creber Units[33] Renergen Acquisition - Renergen shareholder approved the merger on July 10, 2025, with over 99% voting in favor[15] - The company is awaiting final regulatory approval for the Renergen merger, expected imminently[15] - The company listed ASP Isotopes on the Johannesburg Stock Exchange (JSE) on August 27, 2025[15] Financial Highlights - ASP Isotopes had a cash balance of $113.9 million as of September 30, 2025[66] - The company raised $41.7 million of gross proceeds to facilitate acquisitions and business growth[43] - The company received net proceeds of $199.7 million in October 2025 from the issuance of ASP Isotopes common stock[68] - Property and Equipment grew from $22.8 million as of December 31, 2024, to $33.0 million as of September 30, 2025, with approximately 70% for plant construction[68]

Summary of ASP Isotopes (ASPI) Update / Briefing August 28, 2025 Company Overview - **Company**: ASP Isotopes (ASPI) - **Industry**: Isotope production and nuclear energy - **Ticker**: ASPI, traded on NASDAQ Key Points and Arguments 1. **Leadership and Team Introduction**: The call featured Paul Mann (CEO of ASP Isotopes), Rainer Pretorius (CEO of Quantum Leap Energy), and Stefano Marani (CEO of Renurggen), highlighting their backgrounds and expertise in the industry [5][18][19][20]. 2. **Recent Achievements**: - First shipment of enriched silicon to a US customer, crucial for calibrating measurements in production [23]. - Progress in reaching production milestones for Ytterbium-176 and Carbon-12, with a semi-continuous process expected by September [25][26]. - Signed a significant MOU with Fermi for a joint venture to produce nuclear fuels and enrich isotopes in Texas [27]. - Successful listing on the Johannesburg Stock Exchange, enhancing visibility and support from South African stakeholders [28]. 3. **Strategic Partnerships**: The collaboration with Fermi aims to accelerate the production of nuclear fuels and strategically important isotopes for the US market [27][34]. 4. **Market Dynamics**: - The US is projected to become a net importer of helium by 2025-2027, increasing the strategic importance of South African helium production [44][61]. - The semiconductor industry is a major consumer of helium, with its consumption expected to grow significantly [53]. 5. **Production Capabilities**: - Plans to produce lithium-6 and lithium-7 isotopes, which are critical for fusion energy and other applications [39]. - The Fermi site will also focus on producing semiconductor gases and other strategic materials [38]. 6. **Financial Position**: ASP Isotopes reported approximately $70 million in cash on the balance sheet, with plans to explore debt financing options as market conditions evolve [105][106]. 7. **Regulatory Environment**: The company is navigating licensing and regulatory processes for its projects, with government support noted as a positive factor [95][96]. 8. **Future Outlook**: - The company anticipates significant revenue growth from its silicon-28 production, although specific guidance for 2025 and 2026 revenues has not been provided [81]. - The integration of Renurggen and ASP Isotopes aims to create a vertically and horizontally integrated critical materials business, enhancing supply chain reliability for semiconductor fabs [50][59]. Additional Important Content 1. **Helium Market**: Helium's critical role in various industries, including MRIs, semiconductors, and rocketry, was emphasized, with the company positioning itself as a key supplier [87][88]. 2. **Natural Gas Integration**: The business model includes leveraging natural gas as a byproduct of helium production, creating dual revenue streams [71][72]. 3. **Geopolitical Considerations**: The strategic location of South Africa for helium distribution was discussed, highlighting its logistical advantages for global shipping [66]. This summary encapsulates the essential insights from the ASP Isotopes briefing, focusing on the company's strategic initiatives, market positioning, and future growth potential.

Core Insights - ASP Isotopes is preparing for a secondary listing on the Johannesburg Stock Exchange (JSE), with trading expected to commence on August 27, 2025 [3] - The company has successfully shipped its first samples of enriched Silicon-28 to a US customer and anticipates completing the enrichment of Ytterbium-176 by the end of August 2025 [2][5] - The management team will participate in a RedChip Investor call on August 28, 2025, to provide updates on operations and engage with investors [3][16] Corporate Updates - ASP Isotopes has commenced commercial production of Silicon-28 since late March 2025 and shipped its first samples in August 2025 [5] - The company began commercial production of Ytterbium-176 in April 2025, achieving an enrichment factor of 52, with plans to complete the final enrichment batch by the end of August 2025 [7][8] - The company is also enriching Carbon-12 to 99.99% and expects to supply its first commercial product in September 2025, following delays due to regulatory inspections [12] Production and Technology - The company utilizes the Aerodynamic Separation Process (ASP technology) for isotope enrichment, focusing on producing isotopes for healthcare and technology industries [17][18] - ASP Isotopes is transitioning its Ytterbium-176 enrichment plant to a semi-continuous processing method to increase production capacity, despite experiencing a slight delay due to supply chain issues [8] - The company has received permits to import equipment for the enrichment of Nickel-64, Gadolinium-160, and Zinc-68, indicating expansion plans for additional isotopes [9] Market Demand - There is a growing demand for highly enriched Silicon-28 for next-generation semiconductors, which can conduct heat 150% more efficiently than natural Silicon [6] - The company is assessing the potential to expand its Carbon enrichment facility to meet the high demand for both Carbon-12 and Carbon-14 isotopes [12] - The market for isotopes such as Molybdenum-100, Ytterbium-176, and Nickel-64 is expanding, driven by emerging healthcare applications and green energy initiatives [18]